Restenosis-Pipeline Review, H1 2015

Restenosis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6286IDB
  • |
  • Pages: 56
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Restenosis-Pipeline Review, H1 2015


Global Markets Direct's, 'Restenosis-Pipeline Review, H1 2015', provides an overview of the Restenosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Restenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Restenosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Restenosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Restenosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Restenosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Restenosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Restenosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Restenosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Restenosis Overview 7

Therapeutics Development 8

Pipeline Products for Restenosis-Overview 8

Pipeline Products for Restenosis-Comparative Analysis 9

Restenosis-Therapeutics under Development by Companies 10

Restenosis-Therapeutics under Investigation by Universities/Institutes 11

Restenosis-Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Restenosis-Products under Development by Companies 14

Restenosis-Products under Investigation by Universities/Institutes 15

Restenosis-Companies Involved in Therapeutics Development 16

advanceCor GmbH 16

CSPC Pharmaceutical Group Limited 17

CytoTools AG 18

Resverlogix Corp. 19

Shire Plc 20

Viron Therapeutics, Inc. 21

XBiotech USA, Inc. 22

Restenosis-Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Target 24

Assessment by Mechanism of Action 26

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Drug Profiles 32

Annexin A-5-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Antibody Conjugate for Restenosis-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

butylphthalide-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

COR-3-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

CV-18C3-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

HMW-02Ak-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

HMW-02Ap-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

HO-3867-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

LDH-DDART-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

PVS-10200-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Small Molecules for Cardiovascular Diseases-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

VAN 10-4-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

VT-214-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Restenosis-Recent Pipeline Updates 48

Restenosis-Dormant Projects 49

Restenosis-Discontinued Products 51

Restenosis-Product Development Milestones 52

Featured News & Press Releases 52

Nov 20, 2012: XBiotech Reports Positive Phase II Interim Analysis Results Of MABp1 In Vascular Disease 52

Aug 18, 2011: XBiotech Announces Initiation Of Restenosis Clinical Trial In All Five US Sites 53

Dec 22, 2010: XBiotech Files IND For CV-18C3 Monoclonal Antibody Therapy To Treat Peripheral Vascular Disease 54

Appendix 55

Methodology 55

Coverage 55

Secondary Research 55

Primary Research 55

Expert Panel Validation 55

Contact Us 55

Disclaimer 56

List of Tables

Number of Products under Development for Restenosis, H1 2015 8

Number of Products under Development for Restenosis-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Products under Investigation by Universities/Institutes, H1 2015 15

Restenosis-Pipeline by advanceCor GmbH, H1 2015 16

Restenosis-Pipeline by CSPC Pharmaceutical Group Limited, H1 2015 17

Restenosis-Pipeline by CytoTools AG, H1 2015 18

Restenosis-Pipeline by Resverlogix Corp., H1 2015 19

Restenosis-Pipeline by Shire Plc, H1 2015 20

Restenosis-Pipeline by Viron Therapeutics, Inc., H1 2015 21

Restenosis-Pipeline by XBiotech USA, Inc., H1 2015 22

Assessment by Monotherapy Products, H1 2015 23

Number of Products by Stage and Target, H1 2015 25

Number of Products by Stage and Mechanism of Action, H1 2015 27

Number of Products by Stage and Route of Administration, H1 2015 29

Number of Products by Stage and Molecule Type, H1 2015 31

Restenosis Therapeutics-Recent Pipeline Updates, H1 2015 48

Restenosis-Dormant Projects, H1 2015 49

Restenosis-Dormant Projects (Contd..1), H1 2015 50

Restenosis-Discontinued Products, H1 2015 51

List of Figures

Number of Products under Development for Restenosis, H1 2015 8

Number of Products under Development for Restenosis-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Products, H1 2015 13

Assessment by Monotherapy Products, H1 2015 23

Number of Products by Top 10 Targets, H1 2015 24

Number of Products by Stage and Top 10 Targets, H1 2015 25

Number of Products by Top 10 Mechanism of Actions, H1 2015 26

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 27

Number of Products by Top 10 Routes of Administration, H1 2015 28

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 29

Number of Products by Top 10 Molecule Types, H1 2015 30

Number of Products by Stage and Top 10 Molecule Types, H1 2015 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

advanceCor GmbH

CSPC Pharmaceutical Group Limited

CytoTools AG

Resverlogix Corp.

Shire Plc

Viron Therapeutics, Inc.

XBiotech USA, Inc.

Restenosis Therapeutic Products under Development, Key Players in Restenosis Therapeutics, Restenosis Pipeline Overview, Restenosis Pipeline, Restenosis Pipeline Assessment

select a license

Single User License
USD 2000 INR 132860
Site License
USD 4000 INR 265720
Corporate User License
USD 6000 INR 398580



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]